On April 23, 2025 Boston Scientific Corporation (NYSE: BSX) reported net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period (Press release, Boston Scientific, APR 23, 2025, View Source [SID1234652050]). The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term."
First quarter financial results and recent developments:
Reported net sales of $4.663 billion, representing an increase of 20.9 percent on a reported basis, compared to the company’s guidance range of 17 to 19 percent; 22.2 percent on an operational basis; and 18.2 percent on an organic basis, compared to the company’s guidance range of 14 to 16 percent, all compared to the prior year period.
Reported GAAP net income attributable to Boston Scientific common stockholders of $0.45 per share, compared to the company’s guidance range of $0.43 to $0.45 per share, and achieved adjusted EPS of $0.75 per share, compared to the guidance range of $0.66 to $0.68 per share.
Achieved the following net sales growth in each reportable segment, compared to the prior year period:
MedSurg: 11.7 percent reported, 12.8 percent operational and 5.3 percent organic
Cardiovascular: 26.2 percent reported, 27.6 percent operational and 25.6 percent organic
Achieved the following net sales growth in each region, compared to the prior year period:
United States (U.S.): 31.1 percent reported and operational
Europe, Middle East and Africa (EMEA): 5.5 percent reported and 7.9 percent operational
Asia-Pacific (APAC): 8.2 percent reported and 10.6 percent operational
Latin America and Canada (LACA): 4.4 percent reported and 14.1 percent operational
Emerging Markets4: 6.5 percent reported and 9.8 percent operational
Commenced enrollment in the ELEVATE-PF clinical trial to evaluate the safety and effectiveness of the FARAFLEX Mapping and Pulsed Field Ablation (PFA) Catheter for treatment of persistent atrial fibrillation (AF).
Began the OPTION-A clinical trial in the Asia-Pacific region to evaluate the safety and effectiveness of catheter ablation with the FARAPULSE PFA System and subsequent implant of the WATCHMAN Left Atrial Appendage Closure Device in a concomitant procedure.
Published in The New England Journal of Medicine and presented as late-breaking science at the 2025 European Heart Rhythm Association annual meeting were results from the investigator-sponsored SINGLE SHOT CHAMPION clinical trial which demonstrated the FARAPULSE PFA System achieved superior effectiveness for the treatment of symptomatic paroxysmal AF versus the Arctic Front Advance cardiac cryoablation catheter (Medtronic).
Presented late-breaking findings from the VITALYST Early Feasibility Study at the Technology and Heart Failure Therapeutics conference which demonstrated successful early experience with the investigational VITALYST Temporary Percutaneous Transvalvular Circulatory Support System in patients undergoing elective high-risk percutaneous coronary intervention.
Published in JAMA Network Open real-world data demonstrating that patients with prostate cancer treated with SpaceOAR Hydrogel showed a 25% reduction in bowel disorder risk and a 46% decrease in procedures like colonoscopies four years post-radiation therapy.
Completed the acquisition of Bolt Medical, Inc., the developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease.
Announced agreement to acquire SoniVie Ltd., the developer of the TIVUS Intravascular Ultrasound System, an investigational nerve denervation technology designed to treat hypertension — such as renal artery denervation in the kidneys — subject to customary closing conditions.
1. Operational net sales growth excludes the impact of foreign currency fluctuations.
2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.
3. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items.
4.Our Emerging Markets countries include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.
Net sales for the first quarter by business and region:
View News Release Full Screen
Increase/(Decrease)
Three Months Ended
March 31,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational
Basis
Impact of
Certain
Acquisitions/Divestitures
Organic
Basis
(in millions)
2025
2024
Endoscopy
$ 673
$ 642
4.7 %
1.2 %
5.9 %
(0.4) %
5.5 %
Urology
633
513
23.5 %
1.0 %
24.5 %
(20.1) %
4.4 %
Neuromodulation
271
256
5.8 %
0.9 %
6.8 %
— %
6.8 %
MedSurg
1,577
1,412
11.7 %
1.1 %
12.8 %
(7.5) %
5.3 %
Cardiology
2,429
1,872
29.8 %
1.4 %
31.2 %
— %
31.2 %
Peripheral Interventions
656
573
14.4 %
1.4 %
15.8 %
(8.4) %
7.4 %
Cardiovascular
3,085
2,445
26.2 %
1.4 %
27.6 %
(2.0) %
25.6 %
Net Sales
$ 4,663
$ 3,856
20.9 %
1.3 %
22.2 %
(4.0) %
18.2 %
View News Release Full Screen
Increase/(Decrease)
Three Months Ended
March 31,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational
Basis
(in millions)
2025
2024
U.S.
$ 2,960
$ 2,258
31.1 %
— %
31.1 %
EMEA
846
803
5.5 %
2.4 %
7.9 %
APAC
701
647
8.2 %
2.4 %
10.6 %
LACA
155
149
4.4 %
9.6 %
14.1 %
Net Sales
$ 4,663
$ 3,856
20.9 %
1.3 %
22.2 %
Emerging Markets4
$ 690
$ 648
6.5 %
3.3 %
9.8 %
Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.
Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not prepared in accordance with U.S. GAAP.
Guidance for Full Year and Second Quarter 2025
The company estimates net sales growth for the full year 2025, versus the prior year period, to be approximately 15 to 17 percent on a reported basis and 12 to 14 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.86 to $1.93 and estimates adjusted EPS, excluding certain charges (credits), of $2.87 to $2.94.
The company estimates net sales growth for the second quarter of 2025, versus the prior year period, to be in a range of approximately 17.5 to 19.5 percent on a reported basis, and 13 to 15 percent on an organic basis. Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.45 to $0.47 and estimates adjusted EPS, excluding certain charges (credits), of $0.71 to $0.73.
Conference Call Information
Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.